Clinical Trial

Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer (LUST)

Study acronym: LUST
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Multicenter, open-label, parallel-group, phase II randomized study in patients with oligometastatic prostate cancer with 1-3 asymptomatic metastases of the soft tissue or bone. Eligible patients will be randomized at 1:1 ratio to Stereotactic Radiotherapy followed by Lu-PSMA (arm A) or Stereotactic Radiotherapy (arm B)
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-05-30; most recent amendment 2025-12-02.
Status change: Not Yet Recruiting → Recruiting 2023-11-16
Trial Details
NCT Number NCT05893381
Lead Sponsor Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Conditions Prostate Cancer
Enrollment 70 participants
Start Date 2023-06-27
Primary Completion 2027-09 (estimated)
Study Completion 2032-04 (estimated)
Updated on ClinicalTrials.gov 2025-12-03